Opus Genetics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Opus Genetics, Inc. on June 25, 2025. The report discloses a material change in the company's executive leadership regarding the departure of the Chief Financial Officer.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: Nirav Jhaveri, Chief Financial Officer, departed the company on June 25, 2025.
- Reason for Departure: The termination was without cause and was not related to any disagreements regarding accounting principles, financial statement disclosure, or internal controls.
- Severance: Mr. Jhaveri is entitled to severance benefits under his Employment Agreement, subject to the execution of a separation and release agreement.
- Interim Leadership: Amy Rabourn, Senior Vice President of Finance, has been appointed as the interim Principal Financial Officer and Principal Accounting Officer until a permanent successor is named.
Management Commentary and Risks
Management has initiated a search for a permanent successor to the CFO role. The filing explicitly states there are no disagreements with independent auditors or management regarding financial matters. No specific guidance, outlook, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the terms of the severance package for the departing CFO in the Definitive Proxy Statement on Schedule 14A filed on April 2, 2025.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Review the background of interim CFO Amy Rabourn, noting her 20+ years of experience in life sciences finance and prior roles at Gemphire Therapeutics and Pfizer.